Research has shown that every sponsor is looking for faster trial execution, reduced patient burden, and greater patient engagement/retention. The smartest industry leaders are prioritizing more agile methods to achieve this, but why?

In this new insight brief, Science 37 CEO David Coman explains how agile and decentralized approaches actually offer sponsors more centralized command and oversight compared to traditional study design.

Download our Insight Brief to find out more.

Interested in learning more? Register here for our upcoming webinar for more discussion on this topic.